🇺🇸 FDA
Pipeline program

A Study to Assess the Safety of RG6496 in Huntington’s Disease Gene Expansion Carriers with the Selected Genetic Variant (POINT-HD)

BP45378

Phase 1 other active

Quick answer

A Study to Assess the Safety of RG6496 in Huntington’s Disease Gene Expansion Carriers with the Selected Genetic Variant (POINT-HD) for Huntington’s Disease Gene Expansion Carriers is a Phase 1 program (other) at Roche Registration Limited with 1 ClinicalTrials.gov record(s).

Program details

Company
Roche Registration Limited
Indication
Huntington’s Disease Gene Expansion Carriers
Phase
Phase 1
Modality
other
Status
active

Clinical trials